Pediatric Emergency Department, CCSS, Hospital Nacional de Niños "Dr. Carlos Sáenz Herrera", San José, Costa Rica.
Department of Biomedical and Neuromotor Sciences, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
Acta Paediatr. 2021 Jun;110(6):1902-1910. doi: 10.1111/apa.15847. Epub 2021 Mar 26.
This study aims to assess rates of antibiotic prescriptions and its determinants in in children with COVID-19 or Multisystem Inflammatory Syndrome (MIS-C).
Children <18 years-old assessed in five Latin Americas countries with a diagnosis of COVID-19 or MIS-C were enrolled. Antibiotic prescriptions and factors associated with their use were assessed.
A total of 990 children were included: 921 (93%) with COVID-19, 69 (7.0%) with MIS-C. The prevalence of antibiotic use was 24.5% (n = 243). MIS-C with (OR = 45.48) or without (OR = 10.35) cardiac involvement, provision of intensive care (OR = 9.60), need for hospital care (OR = 6.87), pneumonia and/or ARDS detected through chest X-rays (OR = 4.40), administration of systemic corticosteroids (OR = 4.39), oxygen support, mechanical ventilation or CPAP (OR = 2.21), pyrexia (OR = 1.84), and female sex (OR = 1.50) were independently associated with increased use of antibiotics. There was significant variation in antibiotic use across the hospitals.
Our study showed a high rate of antibiotic prescriptions in children with COVID-19, in particular in those with severe disease or MIS-C. Prospective studies are needed to provide better evidence on the recognition and management of bacterial infections in COVID-19 children.
本研究旨在评估 COVID-19 或儿童多系统炎症综合征(MIS-C)患儿的抗生素处方率及其决定因素。
本研究纳入了五个拉丁美洲国家评估的年龄<18 岁的 COVID-19 或 MIS-C 患儿。评估了抗生素的使用情况及其使用的相关因素。
共纳入 990 名儿童:921 名(93%)患有 COVID-19,69 名(7.0%)患有 MIS-C。抗生素使用率为 24.5%(n=243)。伴有(OR=45.48)或不伴有(OR=10.35)心脏受累的 MIS-C、提供重症监护(OR=9.60)、需要住院治疗(OR=6.87)、胸部 X 射线检测到肺炎和/或 ARDS(OR=4.40)、全身皮质类固醇治疗(OR=4.39)、氧疗、机械通气或 CPAP(OR=2.21)、发热(OR=1.84)和女性(OR=1.50)与抗生素使用率增加独立相关。各医院之间抗生素使用存在显著差异。
本研究显示 COVID-19 患儿抗生素使用率较高,尤其是在病情严重或患有 MIS-C 的患儿中。需要前瞻性研究提供更好的证据,以识别和管理 COVID-19 患儿的细菌感染。